ANCHIANO THERAP/S (NASDAQ:ANCN) Downgraded to Market Perform at Oppenheimer

Oppenheimer cut shares of ANCHIANO THERAP/S (NASDAQ:ANCN) from an outperform rating to a market perform rating in a research report report published on Monday morning, Automated Import reports. Oppenheimer currently has $16.00 target price on the stock.

Several other analysts also recently commented on the stock. Zacks Investment Research downgraded shares of ANCHIANO THERAP/S from a buy rating to a hold rating in a report on Tuesday, October 8th. ValuEngine upgraded shares of ANCHIANO THERAP/S from a hold rating to a buy rating in a report on Thursday, August 1st. Finally, LADENBURG THALM/SH SH downgraded shares of ANCHIANO THERAP/S from a buy rating to a neutral rating in a report on Monday. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The company presently has an average rating of Hold and an average price target of $10.42.

ANCN stock traded down $0.13 during mid-day trading on Monday, hitting $1.46. 21,500 shares of the company were exchanged, compared to its average volume of 23,500. The company has a debt-to-equity ratio of 0.04, a quick ratio of 8.61 and a current ratio of 8.61. The firm has a market cap of $14.25 million and a P/E ratio of -0.27. The firm’s 50 day simple moving average is $2.23 and its 200 day simple moving average is $3.45. ANCHIANO THERAP/S has a 1-year low of $1.28 and a 1-year high of $11.50.

An institutional investor recently bought a new position in ANCHIANO THERAP/S stock. FMR LLC bought a new position in shares of ANCHIANO THERAP/S (NASDAQ:ANCN) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 43,000 shares of the company’s stock, valued at approximately $288,000. FMR LLC owned 0.58% of ANCHIANO THERAP/S as of its most recent filing with the SEC. 14.35% of the stock is currently owned by institutional investors.


Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd.

See Also: How Do You Calculate Return on Equity (ROE)?

Receive News & Ratings for ANCHIANO THERAP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANCHIANO THERAP/S and related companies with's FREE daily email newsletter.